Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616
Conference call and webcast scheduled for Thursday, June 13, 2019 at 4:05 p.m. EDT SOUTH SAN FRANCISCO, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat
Toggle Summary Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
Abstract highlights preliminary results from the first two cohorts of the Phase 1b portion of the MISSION Trial in patients with systemic lupus erythematosus (SLE) Detailed poster with additional results will be presented during EULAR 2019 in Madrid SOUTH SAN FRANCISCO, Calif.
Toggle Summary Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior
Toggle Summary Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
Phase 1b systemic lupus erythematosus (SLE) top-line data release and Phase 2 lupus nephritis (LN) initiation on track in Q2 2019 Site selection underway for Phase 2 trial of KZR-616 for the treatment of dermatomyositis (DM) and polymyositis (PM)—trial on track to begin in 2H 2019 FDA accepts
Toggle Summary Kezar Life Sciences to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that Marc Belsky , Chief
Toggle Summary Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced oral and poster
Toggle Summary Kezar Life Sciences Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update
Phase 1b SLE top-line data and Phase 2 LN initiation in Q2 2019 Phase 2 trials in up to four additional autoimmune indications to begin 2H 2019 First clinical candidate nomination for protein secretion program in 2019 SOUTH SAN FRANCISCO, Calif. , March 26, 2019 (GLOBE NEWSWIRE) -- Kezar Life
Toggle Summary Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616
SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the initiation of a Phase 1,
Toggle Summary Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler , Chief
Toggle Summary Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs
SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Celia